P1191 Recombinant adeno-associated virus vector-mediated human VEGF165 gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mice

2003 ◽  
Vol 24 (5) ◽  
pp. 222
Author(s):  
B DEODATO
Keyword(s):  
Wound Healing ◽  
Gene Transfer ◽  
Virus Vector ◽  
Diabetic Mice ◽  
Adeno Associated Virus ◽  
Genetically Diabetic Mice

Long-Term Gene Transfer in Porcine Myocardium After Coronary Infusion of an Adeno-Associated Virus Vector

1996 ◽  
Vol 62 (6) ◽  
pp. 1669-1676 ◽  
Author(s):  
Michael G Kaplitt ◽  
Xiao Xiao ◽  
Richard J Samulski ◽  
Juan Li ◽  
Kaie Ojamaa ◽  
...  
Keyword(s):  
Gene Transfer ◽  
Virus Vector ◽  
Adeno Associated Virus

Improvement in wound healing by a novel synthetic collagen-gel dressing in genetically diabetic mice

2010 ◽  
Vol 22 (2) ◽  
pp. 61-67 ◽  
Author(s):  
Daichi Chikazu ◽  
Tetsushi Taguchi ◽  
Hiroyuki Koyama ◽  
Hisako Hikiji ◽  
Hisako Fujihara ◽  
...  
Keyword(s):  
Wound Healing ◽  
Collagen Gel ◽  
Diabetic Mice ◽  
Genetically Diabetic Mice

scholarly journals Long-Term Enzymatic and Phenotypic Correction in the Phenylketonuria Mouse Model by Adeno-Associated Virus Vector-Mediated Gene Transfer

2004 ◽  
Vol 56 (2) ◽  
pp. 278-284 ◽  
Author(s):  
Hyun-Jeong Oh ◽  
Eun-Sook Park ◽  
Seongman Kang ◽  
Inho Jo ◽  
Sung-Chul Jung
Keyword(s):  
Gene Transfer ◽  
Mouse Model ◽  
Virus Vector ◽  
Adeno Associated Virus

scholarly journals Systemic administration of high-molecular weight hyaluronan stimulates wound healing in genetically diabetic mice

2011 ◽  
Vol 1812 (7) ◽  
pp. 752-759 ◽  
Author(s):  
Mariarosaria Galeano ◽  
Francesca Polito ◽  
Alessandra Bitto ◽  
Natasha Irrera ◽  
Giuseppe M. Campo ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Wound Healing ◽  
High Molecular Weight ◽  
Systemic Administration ◽  
Diabetic Mice ◽  
Genetically Diabetic Mice

scholarly journals Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice

2013 ◽  
Vol 125 (12) ◽  
pp. 575-585 ◽  
Author(s):  
Alessandra Bitto ◽  
Natasha Irrera ◽  
Letteria Minutoli ◽  
Margherita Calò ◽  
Patrizia Lo Cascio ◽  
...  
Keyword(s):  
Wound Healing ◽  
Breaking Strength ◽  
Histological Evaluation ◽  
Concomitant Treatment ◽  
Diabetic Mice ◽  
Vegf Mrna ◽  
Impaired Wound Healing ◽  
Wound Model ◽  
Stromal Cell Derived Factor ◽  
Genetically Diabetic Mice

Diabetic mice are characterized by a disrupted expression pattern of VEGF (vascular endothelial growth factor), and impaired vasculogenesis during healing. Experimental evidence suggests that RLX (relaxin) can improve several parameters associated with wound healing. Therefore we investigated the effects of porcine-derived RLX in diabetes-related wound-healing defects in genetically diabetic mice. An incisional wound model was produced on the back of female diabetic C57BL/KsJ-m+/+Leptdb (db+/db+) mice and their normal littermates (db+/+m). Animals were treated daily with porcine RLX (25 μg/mouse per day, subcutaneously) or its vehicle. Mice were killed on 3, 6 and 12 days after skin injury for measurements of VEGF mRNA and protein synthesis, SDF-1α (stromal cell-derived factor-1α) mRNA and eNOS (endothelial NO synthase) expression. Furthermore, we evaluated wound-breaking strength, histological changes, angiogenesis and vasculogenesis at day 12. Diabetic animals showed a reduced expression of VEGF, eNOS and SDF-1α compared with non-diabetic animals. At day 6, RLX administration resulted in an increase in VEGF mRNA expression and protein wound content, in eNOS expression and in SDF-1α mRNA. Furthermore, the histological evaluation indicated that RLX improved the impaired wound healing, enhanced the staining of MMP-11 (matrix metalloproteinase-11) and increased wound-breaking strength at day 12 in diabetic mice. Immunohistochemistry showed that RLX in diabetic animals augmented new vessel formation by stimulating both angiogenesis and vasculogenesis. RLX significantly reduced the time to complete skin normalization and this effect was abrogated by a concomitant treatment with antibodies against VEGF and CXCR4 (CXC chemokine receptor 4), the SDF-1α receptor. These data strongly suggest that RLX may have a potential application in diabetes-related wound disorders.

Sign in / Sign up

Export Citation Format

Share Document